The HemOnc Pulse
Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Chadi Nabhan, MD, MBA, FACP, covering all topics in the world of hematologic oncology.
Advertisement
Advertisement
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Updates From Other BCT Partners
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
“Blood Cancer Talks" hosts are joined by Dr. Stahl to discuss imetelstat and luspatercept treatment for lower-risk MDS.
Dr. Gerds joins the podcast to discuss how he treats patients with polycythemia vera in his practice.
Dr. Iacoboni joins the podcast to highlight key abstracts from the 2024 ASCO and EHA meetings.
Benjamin Derman, MD, and Manni Mohyuddin, MBBS, look at how MRD factors into clinical decision-making in this disease.
Ayalew Tefferi, MD, gives his assessment of clinical trials in myelofibrosis and describes his own management approaches.
